PolarCool develops the product PolarCap®, which alleviates the effects of concussions. The primary customers are sports clubs and facilities in ice hockey, rugby, football and handball, but also other sports with an increased risk of concussion.

The United Rugby Championship is one of the world's most prominent professional rugby leagues, including the best teams from five different international countries, spanning Ireland, Italy, Scotland, South Africa and Wales.

The agreement includes an introduction of PolarCap® into the league over the next year in all five countries, where one team per country will provide treatment to its concussed players with PolarCap®. The teams providing PolarCap® will include Edinburgh (Scotland), Scarlets (Wales), Zebre Parma (Italy), Connacht (Ireland) and the Vodacom Bulls (South Africa

Following this introduction and after further review, the collective ambition of both the URC and PolarCool is to conduct a one-of-a-kind scientific research project, focused on studying the treatment effect with PolarCap® on concussed players across all URC teams in the league. The project would hope to include support from additional rugby organizations such as World Rugby as well as world-leading researchers in the field.

United Rugby Medical Advisor and Chair of the league's Medical Sub Committee, Dr Michael Dunlop comments:

-In August 2023 it was a pleasure to host a meeting in Edinburgh, attended by a number of the world's leading Medics in Rugby, Concussion, and Hypothermic Medicine as well as URC and PolarCool management. The outcome of which was a shared opinion that it would be good scientific due process to further study the treatment effects of cooling acute concussions in elite rugby with PolarCap®. This current agreement is an essential first step to that. Thanks must go to the Teams involved, and URC and PolarCool.

PolarCool CEO Erik Andersson comments:

-It feels fantastic to have finally achieved this goal. The United Rugby Championship led by Medical Advisor Dr. Michael Dunlop has conducted a thorough due diligence of the evidence surrounding hyperthermia, concussion, and cooling as a treatment. The fact that they now wish to introduce PolarCap® is a great progress, both for PolarCool as a company and for PolarCap® as a treatment method. We now look forward to continued cooperation for a wider implementation and also working towards a research project in collaboration.

The league partnership with the United Rugby Championship holds considerable strategic significance and promises a noteworthy future impact, even though the financial impact of individual team agreements is limited.

This information is information that PolarCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on December 21[st], 2023.

For more information

Erik Andersson - CEO                           
+46 - 73 860 57 00                                                                             
E-mail: erik.andersson@polarcool.se

About PolarCool AB (publ.)

PolarCool AB (publ.) is a medical device company that develops, markets, and sells products for sports medicine. The company focuses on treatment of concussive and sub-concussive brain injury with the portable cooling device PolarCap® System. PolarCool AB (publ.) is based in Lund, Sweden, and its shares are listed on Spotlight Stock Market.